HUTCHMED (China) Limited will host a Research & Development update in Shanghai on October 31, 2025. Dr. Michael Shi will share insights on the Company’s R&D strategy, focusing on its Antibody Targeted Therapy Conjugates platform and lead candidate HMPL-A251. The event will be conducted in Chinese with a live webcast available. A separate webcast in English will also be held. HUTCHMED is a biopharmaceutical company committed to developing targeted therapies for cancer and immunological diseases, with three medicines marketed in China. For more information, visit www.hutch-med.com.

Read more at GlobeNewswire: HUTCHMED to Present R&D Updates on October